Numinus Wellness has collaborated with the Multidisciplinary Association for Psychedelic Studies (MAPS) to provide practitioners with experiential opportunities as part of an investigational Phase I clinical study of MDMA-assisted therapy.
Numinus, through its wholly-owned subsidiary Numinus Wellness Research, submitted a clinical trial application (CTA) for Health Canada approval.
Once approved, the therapy experiential opportunity will be available only through Numinus.
The trial is titled ‘Phase I, open-label, single-arm study to evaluate MDMA experiential training in healthy volunteers and expand knowledge and qualifications of therapists planning to conduct MDMA-assisted therapy (NUMT1).’
It will be carried out using clinical MDMA produced by a Canadian-based drug manufacturer and formulator licensed by Health Canada, Optimi which will supply psychedelic substances for studies.
MAPS founder and president Rick Doblin said: “Our 37-year journey to medicalize the therapeutic use of psychedelics has never been closer to reality, and we’re thrilled to have Numinus as a partner in this work.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Experiential training is an important element of a practitioner’s training in many therapeutic modalities, and through this carefully controlled clinical trial, Numinus is supporting our shared goal of providing training to practitioners who may one day deliver psychedelic-assisted therapy to individuals who need it.”
The study is anticipated to be conducted at Numinus’ clinics in Vancouver and the company is also planning to expand the trial in its additional clinic locations in the future.
Numinus Wellness founder and CEO Payton Nyquvest said: “If the trial protocol is approved, Numinus would be best positioned to provide training with our experiential opportunities.
“Practitioners who complete our MDMA-assisted therapy education programme or have already completed previous MDMA-assisted therapy programs and are qualified to enrol in our Practical Applications course would be able to apply to participate in the experiential clinical trial enabling them to observe, deliver, and receive the therapeutic protocol as part of their training experience.”